title: Prospective Assessment of an innovative test for prostate cancer screening using the VITA process model framework.
abstract: Healthcare innovations are crucial for enhancing patient treatment and a high-quality healthcare system. However, bringing new technologies, methods and procedures into the healthcare market is challenging. Enormous amounts of financial, personnel and organizational resources are required with no upfront certainty for the medical and economic benefit. A new and innovative approach uses interdisciplinary medical, technical and economic expertise to forecast effects of healthcare innovations already at the early research and concept phase of an idea and before major investments are made. A process model framework was developed to operationalize this structured assessment of healthcare innovations. The Visionary Iterative Tailored Approach (VITA) is based on conceptual modeling, simulation and health economics evaluation. Its application for the prospective assessment of an innovative prostate cancer screening is presented.
authors.affiliation: Medical Informatics of the Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: Marion
authors.initials: M
authors.lastname: Gantner-Bär
authors.affiliation: Health Management of the Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Meier
authors.affiliation: Interdisciplinary Centre for Public Health of the Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Kolominsky-Rabas
authors.affiliation: Computer Networks and Communication Systems of the Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: Anatoli
authors.initials: A
authors.lastname: Djanatliev
authors.affiliation: sepp.med GmbH, Röttenbach, Germany.
authors.forename: Armin
authors.initials: A
authors.lastname: Metzger
authors.affiliation: Siemens Healthcare Consulting, Siemens AG, Erlangen, Germany.
authors.forename: Wieland
authors.initials: W
authors.lastname: Voigt
authors.affiliation: Medical Informatics of the Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: Hans-Ulrich
authors.initials: HU
authors.lastname: Prokosch
authors.affiliation: Medical Informatics of the Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Sedlmayr
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D055088:Early Detection of Cancer / Q000191:economics*; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D018803:Models, Economic; D015995:Prevalence; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000191:economics* / Q000453:epidemiology; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013673:Technology Assessment, Biomedical / Q000191:economics / Q000379:methods*
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen